Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

IL-9 as a naturally orthogonal cytokine with optimal JAK/STAT signaling for engineered T cell therapy

Immunity(2025)10.1016/j.immuni.2025.10.024Source: DataRank Database

IL-9 as a naturally orthogonal cytokine with optimal JAK/STAT signaling for engineered T cell therapy is a research paper published in Immunity (2025). On theSindex it has a DataRank of 0.360. It has been cited 10 times.

N/A

0.360DataRank · unranked

Scored on demand from live citation data

Open Access10 citations

Download PDF

Cite:

Linked data & code

geo gen

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (11 grants)Impact (FWCI 4.91)OA: hybridTopics (42)IDs (PubMed, PMC, OpenAlex)Annotations (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.360

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (20)

Sam P. Limsuwannarot ORCID,Kayla Kulhanek ORCID,Aastha Pal,Ossama Labiad,Lea Wenting Rysavy ORCID

Live enrichment

PubMed:41274289 PMC:PMC12643178 OpenAlex:https://openalex.org/W4416738371

NIH National Cancer Institute

Grant: R37CA273074

NIH National Cancer Institute

Grant: K08CA245181

National Institute of General Medical Sciences

Grant: R24GM137786

Damon Runyon Cancer Research Foundation

Grant: R01AI51321

Cancer Research Institute

Grant: CRI14104

Howard Hughes Medical Institute

Grant: 1S10OD026831-01

Howard Hughes Medical Institute

Grant: SCR_017788

NIAID NIH HHS

Grant: R01 AI051321

NIH HHS

Grant: S10 OD026831

Ludwig Institute for Cancer Research Ltd

Parker Institute for Cancer Immunotherapy

FWCI

4.91

Citation Percentile

1.0%

Citation Trend

2026

hybridLicense: cc-by

journalhttps://doi.org/10.1016/j.immuni.2025.10.024

publisherhttps://doi.org/10.1016/j.immuni.2025.10.024

publisherhttps://api.elsevier.com/content/article/PII:S1074761325004789?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1074761325004789?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/41274289

Fields of Study

CAR-T cell therapy researchCytokine Signaling Pathways and InteractionsVirus-based gene therapy researchInterleukin-9Signal TransductionAnimalsJanus KinasesMiceHumansT-LymphocytesSTAT Transcription FactorsReceptors, Interleukin-9Immunotherapy, Adoptive

MeSH Terms

AnimalsHumansT-LymphocytesSignal TransductionImmunotherapy, AdoptiveInterleukin-9STAT Transcription FactorsMiceJanus KinasesReceptors, Interleukin-9

Keywords

Janus kinaseSTAT4statSTAT proteinT cellReceptorEffectorCytokineCellCytokinesCell signalingCancer ImmunotherapyJak/statAdoptive T Cell TherapyIl-9Common Gamma ChainIl-9rCar T Cell TherapyTcr T Cell Therapy

IL-9 as a naturally orthogonal cytokine with optimal JAK/STAT signaling for engineered T cell therapy

FAIR Checklist

DataRank Breakdown

Authors (20)

Funding (11 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)